Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1983 May;40(2):659–664. doi: 10.1128/iai.40.2.659-664.1983

Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model.

S J Cryz Jr, E Fürer, R Germanier
PMCID: PMC264905  PMID: 6551339

Abstract

An experimental leukopenic mouse model was used to evaluate the protective capacities of immunoglobulin G (IgG) fractions directed against toxin A (AT-IgG), elastase (AE-IgG), and lipopolysaccharide (ALPS-IgG) against fatal Pseudomonas aeruginosa infection. Statistically significant protection, as measured by long-term survival, was observed only when mice were treated with serotype-specific ALPS-IgG. The mean lethal dose for P. aeruginosa could be increased by as much as 6,600-fold for mice given ALPS-IgG as compared to mice which received only normal rabbit IgG. ALPS-IgG afforded high levels of protection, even when administered up to 6 h postchallenge. Experiments designed to monitor the growth and spread of a locally administered challenge showed that ALPS-IgG prevented bacteremia and organ colonization, which were pronounced in control animals. The effectiveness of combined antibiotic and immune therapy was tested. Gentamicin alone or in combination with AT-IgG or AE-IgG provided no detectable protection. However, its use with ALPS-IgG afforded substantially higher levels of protection than ALPS-IgG alone.

Full text

PDF
660

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cross A. S., Sadoff J. C., Iglewski B. H., Sokol P. A. Evidence for the role of toxin A in the pathogenesis of infection with Pseudomonas aeruginosa in humans. J Infect Dis. 1980 Oct;142(4):538–546. doi: 10.1093/infdis/142.4.538. [DOI] [PubMed] [Google Scholar]
  2. Crowe K. E., Bass J. A., Young V. M., Straus D. C. Antibody response to Pseudomonas aeruginosa exoproducts in cancer patients. J Clin Microbiol. 1982 Jan;15(1):115–122. doi: 10.1128/jcm.15.1.115-122.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cryz S. J., Jr, Fürer E., Germanier R. Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice. Infect Immun. 1983 Mar;39(3):1067–1071. doi: 10.1128/iai.39.3.1067-1071.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Epstein R. B., Waxman F. J., Bennett B. T., Andersen B. R. Pseudomonas septicemia in neutropenic dogs. I. Treatment with granulocyte transfusions. Transfusion. 1974 Jan-Feb;14(1):51–57. doi: 10.1111/j.1537-2995.1974.tb04484.x. [DOI] [PubMed] [Google Scholar]
  5. Fürer E., Cryz S. J., Jr, Dorner F., Nicolet J., Wanner M., Germanier R. Protection against colibacillosis in neonatal piglets by immunization of dams with procholeragenoid. Infect Immun. 1982 Mar;35(3):887–894. doi: 10.1128/iai.35.3.887-894.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Haghbin M., Armstrong D., Murphy M. L. Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia. Cancer. 1973 Oct;32(4):761–766. doi: 10.1002/1097-0142(197310)32:4<761::aid-cncr2820320405>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  7. Hanessian S., Regan W., Watson D., Haskell T. H. Isolation and characterization of antigenic components of a new heptavalent Pseudomonas vaccine. Nat New Biol. 1971 Feb 17;229(7):209–210. doi: 10.1038/newbio229209a0. [DOI] [PubMed] [Google Scholar]
  8. Harvath L., Andersen B. R., Amirault H. J. Passive immunity against pseudomonas sepsis during granulocytopenia. Infect Immun. 1976 Nov;14(5):1151–1155. doi: 10.1128/iai.14.5.1151-1155.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Harvath L., Andersen B. R. Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia. Infect Immun. 1976 Apr;13(4):1139–1143. doi: 10.1128/iai.13.4.1139-1143.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Harvath L., Andersen B. R., Zander A. R., Epstein R. B. Combined pre-immunization and granulocyte transfusion therapy for treatment of pseudomonas septicemia in neutropenic dogs. J Lab Clin Med. 1976 May;87(5):840–847. [PubMed] [Google Scholar]
  11. Iglewski B. H., Kabat D. NAD-dependent inhibition of protein synthesis by Pseudomonas aeruginosa toxin,. Proc Natl Acad Sci U S A. 1975 Jun;72(6):2284–2288. doi: 10.1073/pnas.72.6.2284. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Iglewski B. H., Sadoff J. C. Toxin inhibitors of protein synthesis: production, purification, and assay of Pseudomonas aeruginosa toxin A. Methods Enzymol. 1979;60:780–793. doi: 10.1016/s0076-6879(79)60071-x. [DOI] [PubMed] [Google Scholar]
  13. Jones C. E., Alexander J. W., Fisher M. Clinical evaluation of Pseudomonas hyperimmune globulin. J Surg Res. 1973 Feb;14(2):87–96. doi: 10.1016/0022-4804(73)90014-0. [DOI] [PubMed] [Google Scholar]
  14. Kawaharajo K., Homma J. Y., Aoyama Y., Okada K., Morihara K. Effects of protease and elastase from Pseudomonas aeruginosa on skin. Jpn J Exp Med. 1975 Apr;45(2):79–88. [PubMed] [Google Scholar]
  15. Kazmierowski J. A., Reynolds H. Y., Kauffman J. C., Durbin W. A., Graw R. G., Jr, Devlin H. B. Experimental pneumonia due to Pseudomonas aeruginosa in leukopenic dogs: prolongation of survival by combined treatment with passive antibody to Pseudomonas and granulocyte transfusions. J Infect Dis. 1977 Mar;135(3):438–446. doi: 10.1093/infdis/135.3.438. [DOI] [PubMed] [Google Scholar]
  16. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  17. Leppla S. H. Large-scale purification and characterization of the exotoxin of Pseudomonas aeruginosa. Infect Immun. 1976 Oct;14(4):1077–1086. doi: 10.1128/iai.14.4.1077-1086.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ohman D. E., Burns R. P., Iglewski B. H. Corneal infections in mice with toxin A and elastase mutants of Pseudomonas aeruginosa. J Infect Dis. 1980 Oct;142(4):547–555. doi: 10.1093/infdis/142.4.547. [DOI] [PubMed] [Google Scholar]
  19. Pavlovskis O. R., Pollack M., Callahan L. T., 3rd, Iglewski B. H. Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections. Infect Immun. 1977 Dec;18(3):596–602. doi: 10.1128/iai.18.3.596-602.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Pennington J. E., Reynolds H. Y., Wood R. E., Robinson R. A., Levine A. S. Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. Am J Med. 1975 May;58(5):629–636. doi: 10.1016/0002-9343(75)90498-2. [DOI] [PubMed] [Google Scholar]
  21. Pier G. B., Sidberry H. F., Sadoff J. C. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2. Infect Immun. 1981 Nov;34(2):461–468. doi: 10.1128/iai.34.2.461-468.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Schimpff S., Satterlee W., Young V. M., Serpick A. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med. 1971 May 13;284(19):1061–1065. doi: 10.1056/NEJM197105132841904. [DOI] [PubMed] [Google Scholar]
  23. Seid R. C., Jr, Sadoff J. C. Preparation and characterization of detoxified lipopolysaccharide-protein conjugates. J Biol Chem. 1981 Jul 25;256(14):7305–7310. [PubMed] [Google Scholar]
  24. Snell K., Holder I. A., Leppla S. A., Saelinger C. B. Role of exotoxin and protease as possible virulence factors in experimental infections with Pseudomonas aeruginosa. Infect Immun. 1978 Mar;19(3):839–845. doi: 10.1128/iai.19.3.839-845.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Woods D. E., Cryz S. J., Friedman R. L., Iglewski B. H. Contribution of toxin A and elastase to virulence of Pseudomonas aeruginosa in chronic lung infections of rats. Infect Immun. 1982 Jun;36(3):1223–1228. doi: 10.1128/iai.36.3.1223-1228.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
  27. Young L. S., Meyer R. D., Armstrong D. Pseudomonas aeruginosa vaccine in cancer patients. Ann Intern Med. 1973 Oct;79(4):518–527. doi: 10.7326/0003-4819-79-4-518. [DOI] [PubMed] [Google Scholar]
  28. Ziegler E. J., Douglas H. Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia. J Infect Dis. 1979 Mar;139(3):288–296. doi: 10.1093/infdis/139.3.288. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES